Our mission is to discover, develop and deliver therapies that will improve the lives of patients with life-threatening illnesses around the world. Gilead makes it a priority to increase access to these medicines for people who can benefit from them, regardless of where they live or their economic status. Today, Gilead works to increase access to its medicines in low- and middle-income countries for HIV/AIDS, viral hepatitis and visceral leishmaniasis.
We focus on the geographic and therapeutic areas where the company and its medicines can make the greatest difference.
Strategic partnerships with other companies and organizations enhance our ability to deliver our medicines to people living in resource-limited countries. These collaborations have been critical to expanding access to our medicines.
Gilead treatment expansion programs are designed to be sustainable, so that patients can continue to benefit for many years to come. To help ensure sustainability at the country level, we support efforts to build local healthcare capacity and strengthen health systems.
We regularly assess our access initiatives and make adjustments as needed in response to lessons learned, stakeholder feedback and evidence of program effectiveness.